Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanomaAnzu-cel showed a 56% confirmed ORR, 14. 6 months mDOR, 6. 1 months mPFS and 16. 2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma Exploratory response analysis suggests continued control of baseline disease and anti-tumor activity across multiple metastatic disease sites with many lesions remaining controlled, some even after progressionFindings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in 1H 2027 Houston, Texas and Tuebingen, Germany, June 1, 2026 - Immatics N.